We are ecstatic to announce that Biocytogen will be attending the 7th EUPLAN International Conference 2025 from September 17th-19th in Wurzburg, Germany! Meet fellow scientists from all levels coming from several countries, and experience the insightful discussions and connections that will be made. Over the course of three days, attend insightful keynote talks from distinguished speakers, enjoy engaging research presentations, and take part in a delightful culinary and wine tasting experience. We hope to share our discoveries in life sciences and make an impact on the future of life sciences!
What is the EUPLAN International Conference?
The EUPLAN (European Platelet Network) International Conference 2025 will be held in Würzburg, Germany, bringing together senior and early-career scientists as well as clinicians from across Europe and beyond. Focused on platelet and megakaryocyte research, the conference aims to foster international collaboration and global connections. It provides an ideal platform for sharing exciting scientific discoveries and advancing both basic and clinical research in the life sciences field. In these 3 days, hear from multiple experienced keynote speakers, listen in on engaging presentations, and experience a delectable culinary wine tasting event.
Event Overview
Date: September 17th-19th, 2025
Venue: Rudolf Virchow Center, Building D15, Josef-Schneider-Str. 2, D-97080 Würzburg, Germany
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you in Würzburg, Germany!
